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Purpose of the study
Primary varicella infection in the HIV population can
have serious sequelae. The HIV non-VZV immune popu-
lation is at risk of attack rates of up to 90% from infected
household contacts, who are predominantly children.
Universal childhood varicella vaccination is currently
under review in Ireland. New recommendations of the
Advisory Committee on Immunisation Practices
(MMWR) 2007 include expanding the use of varicella vac-
cine for HIV-infected adults and adolescents with CD4
>200, with vaccination of household contacts of those
with CD4<200. These guidelines prompted us to review
our HIV patient cohort, 30% of whom are from sub-Saha-
ran Africa (SSA), reflecting the changing demographics of
the Irish population. VZV non-immunity is known to be
higher in the SSA population.
Methods
We undertook a retrospective analysis of all new patients
presenting to our HIV service between 2002 and 2007.
Patient demographics including country of origin, VZV
IgG status and CD4 count were collected. The household
membership of all non-VZV immune patients was
attempted to be ascertained by telephone.
Summary of results
594 HIV-positive patients were tested for Varicella IgG.
544 (91.6%) of these were VZV IgG positive. Of the 50
that were not immune, 42 had CD4 >200. 218 (36.8%) of
the total were from SSA. Of this group, 33 (15%) were
non-immune compared with only 15 (4%) of the Euro-
pean cohort. Non-immune patients with CD4>200 were
contacted by telephone and offered vaccination.This is
currently ongoing. The SSA patients were cautious in dis-
closing their living circumstances. Those non-immune
patients with CD4<200 were advised to seek vaccination
for their household contacts.
Conclusion
Primary varicella infection in the HIV-positive population
poses a credible threat. Our review of VZV immune status
in a cohort of HIV-positive patients identifies the SSA pop-
ulation is a particular "at risk" group. Current guidelines
advise that non-immune patients with CD4 counts >200
can be vaccinated, whereas those with CD4 counts <200
should have their household contacts vaccinated. The
non-immune patients who had CD4>200 were offered
vaccination. Educating patients re household contact vac-
cination is difficult in this population. Inclusion of VZV in
the universal childhood vaccination schedule would help
in this regard. We are presently assessing all patients with
regard to requirement for VZV vaccination, with particular
focus on those who migrated from SSA prior to 2002.
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